Join
Live feed
·
PRReleasevia Quantisnow
Esperion Therapeutics Inc. logo

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

ByQuantisnow·Wall Street's wire, on your screen.
ESPR· Esperion Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ESPR (Esperion Therapeutics Inc.) and more on Quantisnow.